BioSpace: Icosavax’s Nanoparticle VLP-based Vaccine Offers First-in-Class Solution for RSV

BioSpace reporter Gail Dutton reports on Icosavax’s computationally designed virus-like particle (VLP) vaccine platform as a potential first-in-class vaccine for respiratory syncytial virus (RSV).

To read the article, click here.